There is currently no cure for metastatic prostate cancer. Systemic therapy includes hormonal therapy, chemotherapy, immunotherapy and radiotherapy. While most patients will demonstrate initial clinical improvement, it is virtually inevitable that prostate cancer continues to grow or spread despite the current therapies available. The median time for development of ongoing resistance to current treatment options, specifically hormonal treatment, is 9-30 months. Once this occurs, the median duration of survival is 24 months.
The ProstACT study, which commenced in October 2024, is a multinational, multicenter, prospective, randomised, controlled, open-label Phase 3 study to evaluate a new treatment called radionuclide therapy. This is a global study, in conjunction with Telix, and APC is the second site activated globally for Phase 3.
Radionuclide therapy (RNT) employs the use of radioactive substance (radioisotopes) to target specific PSMA tumour cells located in multiple organs and deliver a cytotoxic dose of radiation. The aim is to reduce or even eliminate damage to normal healthy tissue. Prostate Specific Membrane Antigen (PSMA) is a type of protein found on most cancer cells. The intention of this clinical trial is to treat patients with prostate cancer who are PSMA positive.
